MELE Melexis NV

Melexis: update over het aandeleninkoopprogramma

Melexis: update over het aandeleninkoopprogramma

Persbericht - Gereglementeerde informatie



Ieper, België – 9 juni 2025, 17.45 uur CET

Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er 19.334 eigen aandelen ingekocht werden op Euronext Brussel tussen 2 en 6 june 2025.

InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)
2/6/20255.00058,6058,0059,25292.980
3/6/20255.00059,7157,8060,45298.541
4/6/20255.00062,6861,3563,30313.422
5/6/202533463,8663,6064,0021.328
6/6/20254.00064,7164,4065,00258.851
TOTAAL19.33461,3057,8065,001.185.120

Als gevolg van aankopen die zijn gedaan sinds de lancering van het aandeleninkoopprogramma voor maximaal 850.000 aandelen, heeft Melexis nu 478.158 eigen aandelen in bezit.



EN
09/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Melexis NV

 PRESS RELEASE

Melexis: update over het aandeleninkoopprogramma

Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 9 juni 2025, 17.45 uur CET Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er 19.334 eigen aandelen ingekocht werden op Euronext Brussel tussen 2 en 6 june 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)2/6/20255.00058,6058,0059,25292.9803/6/20255.00059,7157,8060,45298.5414/6/20255.00062,6861,3563,30313.4225/6/202533463,8663,6064,0021.3286/6/20254.0...

 PRESS RELEASE

Melexis: update on the share buy-back program

Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 9 June 2025, 17.45 hrs CET Further to the initiation of the share buy-back program announced on 10 December 2024, Melexis reports the purchase of 19,334 Melexis shares on Euronext Brussels in the period from 2 to 6 June 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)2/6/20255,00058.6058.0059.25292,9803/6/20255,00059.7157.8060.45298,5414/6/20255,00062.6861.3563.30313,4225/6/202533463.8663.6064.0021,3286/6/20254,00064.7164.4065.00258,851T...

Pierre FerraguÊ
  • Pierre FerraguÊ

Bible 1Q25 – Autos: recovery on track. Expect strong momentum through ...

Today, we are publishing the automotive section of our 27th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. Auto semi revenues declined, reflecting the ongoing inventory correction. However, nearly all companies have now called the bottom. We expect strong sequential momentum through 2025, which should suppor...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: Reinsurance partnership with TRIGLAV, taking QS on Italian motor direct insurance Belgian Telecoms: Digi introduces a new mobile subscription at €3. Kinepolis: Box office in US/Canada up 76% YoY while France visitors were down 25%. NN Group & ASR: Dutch coalition collapse not affecting Dutch Pension Reform. SBM Offshore: Farewell Aseng after 13.5 years of service. Events Calendar

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update June: Removing Merus, Shurgard and Adyen ...

In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch